Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Antengene Corporation Limited

Equities

6996

KYG039571008

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
0.93 HKD +8.14% Intraday chart for Antengene Corporation Limited +12.05% -53.50%
Mar. 22 Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 20 Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 9,682 5,321 3,070 581 581 -
Enterprise Value (EV) 1 6,573 3,061 1,338 240.1 581 581
P/E ratio -3.31 x -7.61 x -4.69 x -1.93 x -1.17 x -1.42 x
Yield - - - - - -
Capitalization / Revenue - 185 x 19.2 x 18.2 x 4.16 x 1.88 x
EV / Revenue - 185 x 19.2 x 18.2 x 4.16 x 1.88 x
EV / EBITDA -19.3 x -8.77 x -3.55 x -1.82 x -1.07 x -1.28 x
EV / FCF -26,980,554 x -9,157,733 x - - - -
FCF Yield -0% -0% - - - -
Price to Book 3.19 x 2.23 x - - - -
Nbr of stocks (in thousands) 671,181 665,683 674,889 674,889 674,889 -
Reference price 2 14.43 7.993 4.548 0.8609 0.8609 0.8609
Announcement Date 3/25/21 3/18/22 3/28/23 3/22/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - 28.77 160.1 67.3 139.7 308.7
EBITDA 1 -501.6 -606.7 -865.1 -674.4 -542.8 -452.2
EBIT 1 -502.3 -618.2 -878.9 -691.5 -561 -471.1
Operating Margin - -2,148.99% -548.87% -1,027.34% -401.62% -152.63%
Earnings before Tax (EBT) 1 - -655.5 -601.5 -581.2 -475.4 -392.9
Net income 1 -2,929 -655.5 -601.5 -581.2 -475.4 -392.9
Net margin - -2,278.6% -375.61% -863.51% -340.39% -127.28%
EPS 2 -4.364 -1.050 -0.9700 -0.9400 -0.7353 -0.6057
Free Cash Flow -358.9 -581 - - - -
FCF margin - -2,019.67% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 3/25/21 3/18/22 3/28/23 3/22/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - 28.77 53.96 106.2 72.02 -4.711 60.01 77.88
EBITDA - - - - - - - - -
EBIT 1 - -214 -404.3 - -568.5 -339.3 -352.2 -241 -243.7
Operating Margin - - -1,405.22% - -535.44% -471.14% 7,475.12% -401.64% -312.94%
Earnings before Tax (EBT) - - - - - - - - -
Net income - - - - - - - - -
Net margin - - - - - - - - -
EPS 2 - - - - -0.7400 -0.3600 -0.5800 -0.3400 -0.3500
Dividend per Share - - - - - - - - -
Announcement Date 3/25/21 8/20/21 3/18/22 8/31/22 3/28/23 9/27/23 3/22/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position 3,110 2,260 1,732 987 - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow -359 -581 - - - -
ROE (net income / shareholders' equity) -236% -24.1% -29.3% -40.6% -58.3% -63.8%
ROA (Net income/ Total Assets) -148% -22.8% -25.6% - - -
Assets 1 1,977 2,876 2,350 - - -
Book Value Per Share 4.530 3.580 - - - -
Cash Flow per Share - -0.8900 -0.9300 - - -
Capex - 23.4 99.4 - - -
Capex / Sales - 81.3% 62.06% - - -
Announcement Date 3/25/21 3/18/22 3/28/23 3/22/24 - -
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Antengene Corporation Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8609 CNY
Average target price
1.666 CNY
Spread / Average Target
+93.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANTENGENE CORPORATION LIMITED Stock Antengene Corporation Limited
-53.50% 80.18M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. Financials Antengene Corporation Limited